Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) announced it will release its Q3 2022 financial results on November 3, 2022, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and recent company developments. The conference call can be accessed through a registration link provided in the announcement. Akebia, based in Cambridge, Massachusetts, is focused on improving the lives of those impacted by kidney disease.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in ASN Kidney Week 2022, taking place from November 3-6 in Orlando. The company will present a poster titled "Prevalence of Hyporesponse to Erythropoiesis-Stimulating Agents Among Medicare Patients with CKD-Related Anemia" on November 3 from 10:00 a.m. to 12:00 p.m. EDT. Attendees can visit Akebia at Booth #1721 for more information. Founded in 2007 and based in Cambridge, Massachusetts, Akebia focuses on developing therapeutics for kidney disease.
On October 3, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options for 50,000 shares to four new employees, as an inducement for their employment. The options, awarded on September 30, 2022, have an exercise price of $0.32 per share, matching the closing stock price on the grant date. These options vest over four years, beginning with 25% on the first anniversary and the remaining 75% quarterly, contingent on the employees' continued service. The announcement complies with Nasdaq Listing Rule 5635(c)(4).
On September 2, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced granting stock options to six new employees, totaling 27,000 shares, as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.36 per share and will vest over four years, starting with 25% on the first anniversary. This move aims to attract talent crucial for advancing Akebia's mission to improve the lives of those affected by kidney disease.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) has announced that CEO John Butler will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12–14, 2022. This hybrid conference will feature the presentation available on-demand starting September 12 for 90 days via the Investors section of Akebia's website. Akebia aims to improve the lives of those affected by kidney disease and has been operational since its founding in 2007 in Cambridge, Massachusetts.
Akebia Therapeutics reported Q2 2022 financial results showing a 32.4% increase in net Auryxia® product revenue to $43.7M. The company has raised its 2022 revenue guidance for Auryxia to $170 - $175M. Following the termination of their partnership with Otsuka, Akebia regained full rights to vadadustat, which is under review by the FDA and EMA. Operating expenses have decreased due to strategic cost management. Notably, net income reached $29.3M, a shift from a $83.0M loss a year prior.
Akebia Therapeutics (Nasdaq: AKBA) announced initial findings from the VSTAT trial, evaluating vadadustat for treating ARDS in COVID-19 patients with hypoxemia. The phase 2 study included 449 subjects, but failed to meet its primary endpoint, achieving only a 94% probability of benefit at Day 14. Results showed 13.3% of vadadustat participants reached severe outcome scores compared to 16.9% in the placebo group. Adverse events were similar in both groups, with a 78.6% incidence in vadadustat patients. Akebia plans to review full data and consult the FDA for future development.
On August 2, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to six new employees totaling 26,000 shares. The options were granted as inducements for employment, in line with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $0.39 per share, equal to the stock's closing price on the grant date. The options will vest over four years, with an initial 25% vesting on the first anniversary and the remainder vesting quarterly, subject to continued service. Each option has a 10-year term.
Akebia Therapeutics (Nasdaq: AKBA) plans to release its financial results for Q2 2022 on August 4, 2022, after market closure. The company will conduct a conference call at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Listeners can join the call by dialing (833) 630-1955 (domestic) or (412) 317-1836 (international), or access the live webcast via the Investors section of Akebia's website. The call replay will be available from August 4 through August 10, 2022.
On July 5, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to two newly-hired employees, totaling 4,000 shares. These options were awarded to incentivize employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $0.35, which matches the closing stock price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, contingent on continued service. Akebia focuses on therapeutics for kidney disease.